Evidence map›Paper›PMID 29378731›Full record

ArticleJournal of the American Heart Association2018

Neuronal PirB Upregulated in Cerebral Ischemia Acts as an Attractive Theranostic Target for Ischemic Stroke.

Jie Wang, Ying Zhang, Jing Xia, Tingting Cai, Jiawei Du, Jinpeng Chen, Ping Li, Yuqing Shen, Aifeng Zhang, Bo Fu and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Heart Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Nanodrugs for the Treatment of Ischemic Stroke: A Systematic Review.International journal of molecular sciences · 2023
    Pooled it
  2. Immune receptors and aging brain.Bioscience reports · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Jie WangJiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital Medical School Southeast University, Nanjing, China.
Ying ZhangJiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital Medical School Southeast University, Nanjing, China.
Jing XiaKey Laboratory of Developmental Genes and Human Diseases, Ministry of Education, Department of Microbiology and Immunology, Medical School, Southeast University, Nanjing, China.
Tingting CaiJiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital Medical School Southeast University, Nanjing, China.
Jiawei DuJiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital Medical School Southeast University, Nanjing, China.
Jinpeng ChenKey Laboratory of Developmental Genes and Human Diseases, Ministry of Education, Department of Microbiology and Immunology, Medical School, Southeast University, Nanjing, China.
Ping LiKey Laboratory of Developmental Genes and Human Diseases, Ministry of Education, Department of Microbiology and Immunology, Medical School, Southeast University, Nanjing, China.
Yuqing ShenKey Laboratory of Developmental Genes and Human Diseases, Ministry of Education, Department of Microbiology and Immunology, Medical School, Southeast University, Nanjing, China.
Aifeng ZhangKey Laboratory of Developmental Genes and Human Diseases, Ministry of Education, Department of Microbiology and Immunology, Medical School, Southeast University, Nanjing, China.
Bo FuJiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital Medical School Southeast University, Nanjing, China.
Xueren GaoKey Laboratory of Developmental Genes and Human Diseases, Ministry of Education, Department of Microbiology and Immunology, Medical School, Southeast University, Nanjing, China.
Fenqin MiaoKey Laboratory of Developmental Genes and Human Diseases, Ministry of Education, Department of Microbiology and Immunology, Medical School, Southeast University, Nanjing, China.
Jianqiong ZhangJiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital Medical School Southeast University, Nanjing, China zhjq@seu.edu.cn.
Gaojun TengJiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital Medical School Southeast University, Nanjing, China.
Southeast University · CNZhongda Hospital Southeast University · CNNanjing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIschemic stroke is a complex disease with multiple etiologies and clinical manifestations. Paired immunoglobulin-like receptor B (PirB), which is originally thought to function exclusively in the immune system, is now also known to be expressed by neurons. A growing number of studies indicate that PirB can inhibit neurite outgrowth and restrict neuronal plasticity. The aim of the study is to investigate whether PirB can be an attractive theranostic target for ischemic stroke. METHODS AND

resultsFirst, we investigated the spatial-temporal expression of PirB in multiple ischemic stroke models, including transient middle cerebral artery occlusion, photothrombotic cerebral cortex ischemia, and the neuronal oxygen glucose deprivation model. Then, anti-PirB immunoliposome nanoprobe was developed by thin-film hydration method and investigated its specific targeting in vitro and in vivo. Finally, soluble PirB ectodomain (sPirB) protein delivered by polyethylene glycol-modified nanoliposome was used as a therapeutic reagent for ischemic stroke by blocking PirB binding to its endogenous ligands. These results showed that PirB was significantly upregulated after cerebral ischemic injury in ischemic stroke models. Anti-PirB immunoliposome nanoprobe was successfully developed and specifically bound to PirB in vitro. There was accumulation of anti-PirB immunoliposome nanoprobe in the ischemic hemisphere in vivo. Soluble PirB ectodomains remarkably improved ischemic stroke model recovery by liposomal delivery system.

conclusionsThese data indicated that PirB was a significant element in the pathological process of cerebral ischemia. Therefore, PirB may act as a novel theranostic target for ischemic stroke.

Indexed as

NanoparticlesSpectroscopy, Near-InfraredAnimalsApoptosisBiomarkersBrainCells, CulturedInfarction, Middle Cerebral ArteryLigandsLiposomesMagnetic Resonance ImagingMaleMice, Inbred C57BLMolecular ImagingNeuronsPeptide FragmentsBiomarkersLigandsLiposomesPeptide FragmentsPirb protein, mouseReceptors, Immunologicimagingischemic strokeliposomePirBtherapy

Identifiers

PMID29378731
PMCPMC5850238
OpenAlexW2793506053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.